Viking Therapeutics Inc (VKTX) — Cash Flow-to-Debt Ratio
Viking Therapeutics Inc (VKTX) has a Cash Flow-to-Debt Ratio of -1.11x as of December 2025, meaning its operating cash flow of $-85.29 Million could theoretically repay -1% of its total liabilities ($76.67 Million) in one year. Check Viking Therapeutics Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Viking Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Viking Therapeutics Inc across 14 annual periods. Also explore balance sheet size of Viking Therapeutics Inc for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Viking Therapeutics Inc (2012–2025)
Year-by-year debt coverage analysis for Viking Therapeutics Inc. For market capitalisation and broader financial context, see Viking Therapeutics Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.15x | $-87.79 Million | $76.67 Million | ▲ +63.4% |
| 2024 | -3.13x | $-87.79 Million | $28.04 Million | ▲ +14.4% |
| 2023 | -3.66x | $-73.38 Million | $20.07 Million | ▼ -75.3% |
| 2022 | -2.09x | $-48.40 Million | $23.21 Million | ▲ +61.5% |
| 2021 | -5.42x | $-47.59 Million | $8.78 Million | ▼ -202.7% |
| 2020 | -1.79x | $-21.78 Million | $12.16 Million | ▲ +48.4% |
| 2019 | -3.47x | $-24.75 Million | $7.14 Million | ▲ +15.6% |
| 2018 | -4.11x | $-18.75 Million | $4.56 Million | ▼ -141.1% |
| 2017 | -1.70x | $-14.76 Million | $8.66 Million | ▲ +0.0% |
| 2016 | -1.71x | $-11.07 Million | $6.49 Million | ▼ -31.1% |
| 2015 | -1.30x | $-8.73 Million | $6.71 Million | ▼ -1957.0% |
| 2014 | -0.06x | $-1.59 Million | $25.17 Million | ▲ +65.2% |
| 2013 | -0.18x | $-78.23K | $431.00K | ▼ -9467.5% |
| 2012 | 0.00x | $-200.00 | $105.42K | — |